Clinical Trial Update: Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg [Phase 1]

View source ↗

Summary

A Phase 1 study comparing the pharmacokinetic characteristics and safety of Dilatrend sustained-release 32 mg capsules versus Dilatrend 25 mg tablets.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension
• Heart Failure
• Stable Angina

Drugs mentioned

• Dilatrend SR Capsule 32mg (carvedilol)
• Dilatrend Tablet 25mg (carvedilol)

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Essential Hypertension, Chronic Stable Angina | Phase 1 | Status: UNKNOWN